Laboratory analyzers MEDCAPTAIN Immu F6, SARS-CoV-2 NAbs, etc.

Immu F6 automatic analytical systems for on-site examination using direct chemiluminescence technology with acridinium ether provide accurate quantitative results in the analysis of whole blood, and are also suitable for emergency care and clinical use.

The technology of direct chemiluminescence with acridinium ether is implemented in the certified analysis on the NAT SARS-CoV-2 of the company MEDCAPTAIN . This kit is useful for modern studies of seroprevalence to COVID-19, assessment of immunity and effectiveness of various candidate vaccines.

SARS-CoV-2 assays (both IgG and IgM) also use direct chemiluminescence technology to detect immunoglobulins. This solution is based on high sensitivity for reliable and rapid screening of people who have been in contact with patients with SARS-CoV-2, guarantees accurate results for infection, since which a little time has passed, and serves as the basis for further assessment of the course of COVID-19. The kit can also be used with fully automated chemiluminescent analyzers of the SMART series.

Rapid antigen tests diagnose acute COVID-19 infection in 15 minutes and are recommended by WHO. Rapid diagnostic tests for SARS-CoV-2 antigens that meet the minimum functional requirements can be used to diagnose SARS-CoV-2 infection in conditions where MANC is not available or when a long processing time hinders clinical use.

Models: Immu F6, SARS-CoV-2 NAbs (CLIA), SARS-CoV-2 (IgG, IgM).